182 related articles for article (PubMed ID: 38143233)
21. [Radiotherapy treatment of lymphoma].
Juretić A; Zivković M; Samija M; Cović D; Bistrović M; Viculin T; Bagović D; Tomek R
Lijec Vjesn; 2000; 122(11-12):283-91. PubMed ID: 11291272
[TBL] [Abstract][Full Text] [Related]
22. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
Paumier A; Ghalibafian M; Beaudre A; Ferreira I; Pichenot C; Messai T; Lessard NA; Lefkopoulos D; Girinsky T
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):199-205. PubMed ID: 21481723
[TBL] [Abstract][Full Text] [Related]
23. [Role of radiotherapy in haematology].
Peignaux-Casasnovas K; Truc G; Rossi C; Casasnovas O
Cancer Radiother; 2021 Oct; 25(6-7):603-606. PubMed ID: 34462212
[TBL] [Abstract][Full Text] [Related]
24. Recommendations for the use of radiotherapy in nodal lymphoma.
Hoskin PJ; Díez P; Williams M; Lucraft H; Bayne M;
Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):49-58. PubMed ID: 22889569
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
26. CAR-T cell therapy for patients with hematological malignancies. A systematic review.
Pasqui DM; Latorraca CDOC; Pacheco RL; Riera R
Eur J Haematol; 2022 Dec; 109(6):601-618. PubMed ID: 36018500
[TBL] [Abstract][Full Text] [Related]
27. Current approaches to the management of pediatric Hodgkin lymphoma.
Freed J; Kelly KM
Paediatr Drugs; 2010 Apr; 12(2):85-98. PubMed ID: 20218745
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
29. Modeling growth kinetics and statistical distribution of oligometastases.
Withers HR; Lee SP
Semin Radiat Oncol; 2006 Apr; 16(2):111-9. PubMed ID: 16564446
[TBL] [Abstract][Full Text] [Related]
30. INFRADIAPHRAGMAL RADIOTHERAPY IN PATIENTS WITH LYMPHOMA: VOLUME DEFINITION AND SIDE EFFECTS.
Galunić-Bilić L; Šantek F
Acta Clin Croat; 2018 Sep; 57(3):554-560. PubMed ID: 31168189
[TBL] [Abstract][Full Text] [Related]
31. A systematic overview of radiation therapy effects in Hodgkin's lymphoma.
Gustavsson A; Osterman B; Cavallin-Ståhl E
Acta Oncol; 2003; 42(5-6):589-604. PubMed ID: 14596517
[TBL] [Abstract][Full Text] [Related]
32. The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.
Constine LS; Yahalom J; Ng AK; Hodgson DC; Wirth A; Milgrom SA; Mikhaeel NG; Eich HT; Illidge T; Ricardi U; Dieckmann K; Moskowitz CH; Advani R; Mauch PM; Specht L; Hoppe RT
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1100-1118. PubMed ID: 29722655
[TBL] [Abstract][Full Text] [Related]
33. [Radiotherapy indications in non-Hodgkin lymphoma].
Quero L; Hennequin C; Brice P
Cancer Radiother; 2009 Oct; 13(6-7):471-8. PubMed ID: 19695926
[TBL] [Abstract][Full Text] [Related]
34. Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases.
Li X; Brownlee NA; Sporn TA; Mahar A; Roggli VL
Arch Pathol Lab Med; 2015 Sep; 139(9):1129-36. PubMed ID: 25844559
[TBL] [Abstract][Full Text] [Related]
35. [Hodgkin lymphoma].
Itami J
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Apr; 62(5):215-20. PubMed ID: 12043226
[TBL] [Abstract][Full Text] [Related]
36. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
37. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
38. Global burden of hematologic malignancies and evolution patterns over the past 30 years.
Zhang N; Wu J; Wang Q; Liang Y; Li X; Chen G; Ma L; Liu X; Zhou F
Blood Cancer J; 2023 May; 13(1):82. PubMed ID: 37193689
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies.
Saiz LC; Leache L; Gutiérrez-Valencia M; Erviti J; Rojas Reyes MX
Ther Adv Hematol; 2023; 14():20406207231168211. PubMed ID: 37138698
[TBL] [Abstract][Full Text] [Related]
40. Treatment Options for Recurrent Primary CNS Lymphoma.
Kaulen LD; Baehring JM
Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
